Background: syndrome of menopause (GSM) is a chronic and progressive condition. The adverse events (AEs) and contraindications of hormonal therapy have generated interest in vaginal laser treatment. The non-ablative wavelength 1540 nm (GaAs) in this mixed laser synergistically enhances the 10,600 nm (CO2) effect, providing a deeper hyperthermic stimulation of collagen and elastin without damaging the superficial layers. This results in fewer AEs, and reverses vaginal atrophy (VA) while reducing the 10,600 nm laser power to 5W. The aim of the study is to evaluate the efficacy and safety of a mixed-wavelength laser in alleviating GSM symptoms compared to sham.
Patients And Methods: A randomized single-blind sham-controlled trial was conducted. 31 postmenopausal women with Vaginal Maturation Value (VMV <50%) were randomized into laser or sham intervention groups, receiving three monthly treatments. VMV, vaginal pH, and GSM symptoms severity were measured at 3- and 9-months post-intervention, and AE were assessed.
Results: 27 patients completed the study; 14 were randomly assigned to the laser and 13 to the sham group. At 3 months, VMV improved by 12.4% compared to the sham group (P= 0.033), indicating a significant reversal of VA and a significant patient global improvement (P=0.030). At 9 months, dyspareunia decreased significantly (P = 0.049), while other symptoms and patient satisfaction demonstrated a significant improvement trend. However, VMV in the laser group returned to baseline values. Vaginal pH remained unchanged. The laser intervention was well tolerated, with mild and self-limited AEs.
Conclusion: The mixed wavelength laser enables a reduction of 10,600 nm laser power, enhancing its safety profile while achieving promising outcomes in GSM. It is a safe, well-tolerated, and effective alternative for GSM treatment when conventional therapies fail. Further studies with larger samples, varied settings, and extended follow-up are needed to assess its long-term efficacy and side effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887494 | PMC |
http://dx.doi.org/10.2147/IJWH.S486323 | DOI Listing |
Altern Ther Health Med
March 2024
Objective: The study aims to assess the effect of Information, Motivation, Behavior Skills (IMB) model-based sleep counseling program on the quality of life and sleep quality in postmenopausal women with sleep problems.
Methods: The study design includes a randomized controlled experiment with pre-test and post-test control groups. The study was conducted with 175 postmenopausal women (IMB Group:85, control group:90) who visited Konyaalti Municipality Social Services Center between March 2018 and May 2019 and met the inclusion criteria for the research.
Endokrynol Pol
March 2025
Department of Endocrine Disorders and Bone Metabolism, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Introduction: The authors of the latest recommendations state that osteoporosis diagnosis should not rely solely on densitometric (DXA) criteria. Fracture risk assessment is crucial for determining diagnosis and intervention thresholds. Comprehensive assessment of fracture risk requires consideration of bone mineral density (BMD) results, use of risk calculators like Fracture Risk Assessment Tool (FRAXTM), and analysis of clinical and lifestyle factors.
View Article and Find Full Text PDFEndokrynol Pol
March 2025
Department of Endocrine Disorders and Bone Metabolism, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Introduction: A densitometric diagnosis of osteoporosis qualifies patients to a diagnostic-therapeutic process, but densitometric evaluation may not be sufficient for osteopaenic patients. Therefore, it is essential to assess osteoporosis risk factors, fracture history, and 10-year fracture risk, and classify patients into low-, medium-, high-, or very high-risk categories. In our study, we aimed to assess the risk of fractures in patients with newly diagnosed osteopaenia and determine the percentage of patients at high and very high risk of fracture.
View Article and Find Full Text PDFJ Natl Cancer Inst
March 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined risk of cardiovascular disease (CVD) events and mortality associated with endocrine therapy use in postmenopausal women with early-stage BC.
Methods: Postmenopausal women diagnosed with stage I-III hormone receptor-positive BC from 2005 to 2013 were included (n = 8,495).
J Endocr Soc
March 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, F-59000 Lille, France.
Context: Noninvasive measurement of bone marrow adipose tissue using magnetic resonance imaging and proton density fat fraction (PDFF) may enhance clinical fractures prediction in postmenopausal women.
Objective: This study aimed to assess the association between PDFF measurements and clinical fracture incidence.
Methods: A longitudinal study was conducted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!